Clinic
Purnachandra R Yerneni MD
Purnachandra R Yerneni MD was paid $205K by Medicaid between Jan 2018 and Jun 2022, across 17 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 57% of everything it billed.
33Billing provider infoPURNACHANDRA R YERNENI MD
BOGALUSA, LA 70427
BOGALUSA, LA 70427
33aNPI1073777843assigned 07/10/2008
33bProvider typePrimary Care Clinic/Center
28Total paid$205K
24GClaims10,918
24DCodes billed17
24AFirst – last monthJan 2018 – Jun 2022
Compared with peers
Next to other Primary Care Clinic/Center providers in Louisiana
Rank by total paid#45 of 92
Median peer was paid$157K
This provider vs. median1.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 1,634 | $28K | |
| 2019 | 5,037 | $96K | |
| 2020 | 2,857 | $48K | |
| 2021 | 1,106 | $25K | |
| 2022 | 284 | $8K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 57% | 3,060 | 1,831 | $117K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 16% | 466 | 386 | $32K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 8.7% | 2,186 | 1,107 | $18K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 6.1% | 523 | 290 | $12K |
| 82947 | 4.6% | 2,816 | 1,458 | $9K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 3.3% | 260 | 195 | $7K |
| 99442 | 1.6% | 221 | 105 | $3K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1.3% | 227 | 206 | $3K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 37 | 27 | $2K |
| 90674 | <1% | 32 | 30 | $646.99 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 33 | 30 | $382.20 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 34 | 20 | $46.86 |
5 more codes
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 405 | $24.89 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 17 | $1.28 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 0% | 436 | $0.00 |
| 3008F | 0% | 132 | $0.00 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 33 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialYERNENI, PURNACHANDRA (OWNER/PRESIDENT)